New Freight Pricing Model Raises Costs for Gorey Businesses Local Concerns Mount SP 500 Edges Higher as Technology Rally Counteracts Energy Slide Reddit Shares Slide Nearly 6 After Meta Launches Facebook Groups Standalone App Forum Amazon Health Chief Steps Down Amwell Cofounder Dr Roy Schoenberg to Take Over ATT CEO Highlights Growing Demand for Skilled BlueCollar Workers in AIDriven Economy US and China Trade Rifts Persist After TrumpXi Summit APEC Signals Show USAS Q1 2026 Earnings EPS Misses Estimates Stock Rises Despite Negative Surprise TPCS Q1 2026 Earnings Net Loss of 015 Per Share Amid Operational Adjustments Camden Property Trust CPT Q1 2026 Earnings Strong EPS Beat Signals Resilient Multifamily Operations TULP Q4 2014 Earnings EPS Misses Estimates Significantly GOOGL Q1 2026 Earnings EPS Miss Amidst AI Investment Pressures SPRY Q1 2026 Earnings EPS Misses Estimates as PreRevenue Stage Continues Summit Hotel Properties INN Inches Higher as Hospitality Sector Navigates Uncertain Terrain DiaMedica Therapeutics DMAC Gains 4 as Stock Approaches Key Resistance Level Walmart WMT Edges Lower as Retail Sector Faces Headwinds Phillips Edison Company PECO Shows Modest Gain Testing Key Resistance Zone Definium Therapeutics DFTX Slips 066 as Shares Test Key Support Zone XFAB Shares Surge Following Social Media Post Retail Activity Drives Trading on Tradegate HTO Q1 2026 Earnings EPS Beats Estimates by 533 Shares Dip Modestly Georgia Power Preferred Notes GPJA Edge Lower Amid Cautious Trading KALV Q1 2026 Earnings Narrower Loss Beats Expectations Clinical Pipeline Progress Underway ABM Q1 2026 Earnings EPS Misses Estimates as Stock Slips Slightly TKC Q4 2025 Earnings Mixed Performance Amidst Currency Headwinds and Margin Pressures Willis Lease Finance Corporation WLFC Q1 2026 Earnings Strong EPS Beat Driven by Asset Utilization and Leasing Demand ELAN Q1 2026 Earnings EPS Surprise Drives Positive Reaction FrontView REIT FVR Q1 2026 Earnings Strong Earnings Beat Driven by Operational Efficiency KAPA Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Advances Clinical Pipeline